AbbVie Inc (ABBV)vsPharming Group NV (PHAR)
ABBV
AbbVie Inc
$291.27
+1.07%
HEALTHCARE · Cap: $521.11B
PHAR
Pharming Group NV
$12.29
-0.08%
HEALTHCARE · Cap: $867.74M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 16969% more annual revenue ($66.01B vs $386.75M). ABBV leads profitability with a 15.7% profit margin vs 6.3%. PHAR trades at a lower P/E of 38.3x. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
PHAR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.27
$133.98 premium
Margin of Safety
-32.3%
Fair Value
$11.77
Current Price
$12.29
$0.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 33.9%
Earnings expanding 74.9% YoY
Reasonable price relative to book value
Revenue surging 20.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 3.4% — below average capital efficiency
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : PHAR
The strongest argument for PHAR centers on Operating Margin, EPS Growth, Price/Book. Revenue growth of 20.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : PHAR
The primary concerns for PHAR are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while PHAR is a growth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.23 — expect wider price swings.
PHAR is growing revenue faster at 20.8% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 55/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Pharming Group NV
HEALTHCARE · BIOTECHNOLOGY · USA
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?